Angelos Dovletoglou, Ph.D.
Angelos is the senior vice president of technical operations for Origin Biosciences, a BridgeBio company. Throughout his career, Angelos has held positions of increasing responsibility in CMC, preclinical development, manufacturing, quality, program & alliance management, clinical operations and global regulatory affairs. Prior to Origin he established the CMC and preclinical development functions at Epizyme and served as the head of regulatory affairs. Dr. Dovletoglou oversaw the early development work on pinometostat and tazemetostat, co-chaired the two JSC teams, achieved key milestones across various functions, and successfully manufactured DS/DP for the clinical studies in the US, EU and Asia. Prior to Epizyme, Angelos served as a CMC scientist and manager at Biogen, Momenta Pharma and Merck Research Laboratories contributing to the development, registration and successful commercial launch of 7 NCEs. Angelos also served as a member of the scientific advisory board at Cocoon Biotech developing novel OA therapies, and chair of the Specifications and BACPAC Working Group at PQRI. He has numerous publications/patents to his name, as well as several therapies on the market that improve the lives of patients. Dr. Dovletoglou earned his Ph.D. in inorganic chemistry from the University of North Carolina at Chapel Hill and B.S. in Chemistry from the University of Athens, Greece. Outside of work, Angelos enjoys time with his family, friends and riding his fat bike in the snow.